111 related articles for article (PubMed ID: 24481640)
1. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
Hertzberg M; Matthews JP; Stone JM; Dubosq MC; Grigg A; Ellis D; Benson W; Browett P; Horvath N; Januszewicz H; Abdi E; Green M; Bonaventura A; Marlton P; Cannell P; Wolf M;
Am J Hematol; 2014 May; 89(5):536-41. PubMed ID: 24481640
[TBL] [Abstract][Full Text] [Related]
2. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
[TBL] [Abstract][Full Text] [Related]
3. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G
Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793
[TBL] [Abstract][Full Text] [Related]
4. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
[TBL] [Abstract][Full Text] [Related]
7. [Biweekly cyclophosphamide, epirubicin, vincristine and prednisolone (CEOP) chemotherapy for the elderly patients with aggressive non-Hodgkin's lymphoma. Tochigi Malignant Lymphoma Study Group for the Elderly Patients].
Izumi T; Muroi K; Hoshino Y; Komatsu N; Ohtsuki T; Yamada M; Tomizuka H; Hatake K; Furusawa S; Miura Y
Gan To Kagaku Ryoho; 1996 May; 23(6):797-800. PubMed ID: 8645033
[No Abstract] [Full Text] [Related]
8. Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma.
Newell M; Goldstein D; Milliken S; Lewis C; Hoy J; Thomson B; Cooper D
Ann Oncol; 1996 Dec; 7(10):1029-36. PubMed ID: 9037361
[TBL] [Abstract][Full Text] [Related]
9. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.
Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H
Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756
[TBL] [Abstract][Full Text] [Related]
10. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group.
Economopoulos T; Psyrri A; Dimopoulos MA; Kalogera-Fountzila A; Pavlidis N; Tsatalas C; Nikolaides C; Mellou S; Xiros N; Fountzilas G
Cancer J; 2007; 13(5):327-34. PubMed ID: 17921732
[TBL] [Abstract][Full Text] [Related]
11. Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
Avilés A; Nambo MJ; Talavera A; Garcia EL; Huerta-Guzman J; Díaz Maqueo JC
Anticancer Drugs; 1997 Nov; 8(10):937-42. PubMed ID: 9436636
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
[TBL] [Abstract][Full Text] [Related]
14. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
[TBL] [Abstract][Full Text] [Related]
15. CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomas.
Abate G; Tafuto S; Romano A; Gailli E; Corazzelli G
Haematologica; 1992; 77(4):322-5. PubMed ID: 1385277
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
Comella P; Abate G; Fiore M; Di Finizio G; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1257-8. PubMed ID: 16312856
[No Abstract] [Full Text] [Related]
17. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
18. CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.
Cai MC; Cheng S; Wang X; Hu JD; Song YP; Huang YH; Yan ZX; Jiang YJ; Fang XS; Zheng XY; Dong LH; Ji MM; Wang L; Xu PP; Zhao WL
Genome Med; 2020 Apr; 12(1):41. PubMed ID: 32349779
[TBL] [Abstract][Full Text] [Related]
19. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H
Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Chamorey E; Gressin R; Peyrade F; Rossi JF; Lepeu G; Foussard C; Harrousseau JL; Fabbro M; Richard B; Delwail V; Maisonneuve H; Vilque JP; Thyss A
Oncology; 2005; 69(1):19-26. PubMed ID: 16088231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]